Obesity drugs, or GLP-1s, have had a transformative effect on Wall Street and waistlines over recent years. As adoption grows and new applications for the drugs come to light, experts say that could ...

Forbes contributors publish independent expert analyses and insights. Across the earlier articles in this series, we developed a framework for understanding why weight loss and regulation is far more ...

Weight loss drugs are proving to be super popular among many workers with job-based health insurance. But GLP-1 medications are busting their employers’ budgets, leading some firms to rethink their ...

GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity or overweight with a related health condition. Read on for everything you need to know about GLP-1s for weight loss, ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The pill also improved cardiovascular risk factors and physical activity levels.

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. Injectable weight loss medications — also ...

Novo Nordisk has had a difficult year as investors questioned the company's ability to translate its strides in pioneering GLP-1 drugs to financial gains. Scientists, however, say that Novo's medicine ...

Ozempic started the weight-loss drug frenzy, and it continues to be a famous name in the fight against obesity, even though it's not approved for that purpose. The blockbuster medication is meant to ...

Blockbuster weight-loss shots are undergoing a major makeover. Drugs like Zepbound and Wegovy have already taken the US by storm — with the number of Americans using them to slim down more than ...

Weight loss restored healthy metabolism in both young and mid-aged mice, but the brain told a different story. In mid-aged animals, slimming down actually worsened inflammation in a brain region tied ...

Rachel Woods does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...